Co-Diagnostics Inc Stock Price, News & Analysis

Co-Diagnostics (NASDAQ:CODX) has announced a registered direct offering of 9,619,000 shares of common stock priced at $0.40 per share, aiming to raise approximately $3.8 million in gross proceeds. The offering is priced at-the-market under Nasdaq rules and is expected to close around September 18, 2025.

The molecular diagnostics company plans to use the proceeds for working capital and general corporate purposes. Maxim Group LLC is serving as the sole placement agent for the offering, which is being conducted under an effective S-3 shelf registration statement.

Co-Diagnostics (NASDAQ:CODX) has signed a strategic Memorandum of Understanding (MOU) with a partner in Saudi Arabia to establish a joint venture for manufacturing and distributing its Co-Dx™ PCR platform across the Middle East and North Africa (MENA) region.

The planned JV aligns with Saudi Arabia's Vision 2030 initiatives and follows a similar model to CODX's Indian joint venture, CoSara Diagnostics. The Saudi partner will provide local operational support, infrastructure, personnel, and regulatory expertise throughout the MENA region. Saudi Arabia represents one of the largest international markets for CODX's Logix Smart® tests.

The Co-Dx PCR platform, including PCR Home™ and PCR Pro™, is currently pending regulatory review and is not yet available for sale.

Co-Diagnostics (NASDAQ:CODX) has completed an in silico analysis of its Co-Primers®-based PCR tests for chikungunya virus (CHIKV) detection. The analysis demonstrated high homology against over 1,200 CHIKV sequences and confirmed reactivity against recent virus strains.

The company's Logix Smart® ZDC Test, CE-marked since 2019, can detect and differentiate between Zika, dengue, and chikungunya viral RNA. Additionally, CODX's Vector Smart® VZDC Test is used by 30 mosquito abatement districts across 20 U.S. states for environmental testing. The company's Indian joint venture, CoSara Diagnostics, has received clearance to manufacture and sell its SaraGene™ Dengue and Chikungunya Multiplex RT-PCR test.

Co-Diagnostics (NASDAQ:CODX) has been recognized at the Utah Business 2025 Innovation Awards Summit for its Co-Dx PCR platform in the Healthcare and Life Sciences category. The platform, which includes the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and associated tests and software, was honored for its innovative approach to molecular diagnostics.

CEO Dwight Egan accepted the award, highlighting the company's commitment to expanding access to high-quality PCR diagnostics globally. The platform is currently pending regulatory review by the FDA and other bodies, with commercialization expected in 2026.

Co-Diagnostics (Nasdaq: CODX) announced its participation at the 17th Annual Next Generation Dx Summit from August 18-20, 2025, at the Capital Hilton in Washington, D.C. The company will showcase its Logix Smart® clinical laboratory solutions at Booth #12 and provide information about its upcoming Co-Dx PCR diagnostics platform.

The summit serves as a platform for international thought leaders in diagnostic advancement and technology innovation. Visitors can learn about CODX's pipeline of upper respiratory, tuberculosis and HPV tests planned for clinical evaluations in 2025. The company's attendance is partially funded by a World Trade Center Utah grant.

Co-Diagnostics (NASDAQ: CODX) released its Q2 2025 financial results, reporting revenue of $0.2 million, down from $2.7 million in Q2 2024, primarily due to timing of grant revenue recognition. The company posted a net loss of $7.7 million ($0.23 per share) compared to a $7.6 million loss ($0.25 per share) in Q2 2024.

Operating expenses decreased by 19.1% to $8.2 million, while cash and equivalents stood at $13.4 million. The company remains on track with its Co-Dx PCR platform development, preparing to initiate clinical evaluations for all tests before year-end, with enhanced COVID-19 test trials beginning imminently.

Co-Diagnostics (NASDAQ:CODX), a molecular diagnostics company, has scheduled its second quarter 2025 earnings release for Thursday, August 14, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day.

Key executives participating in the call include CEO Dwight Egan, CFO Brian Brown, and Head of IR Andrew Benson. Investors can access the webcast through the company's IR website and join the conference call via toll-free (888-880-3330) or toll (646-357-8766) numbers. A recording will be available on the company's website for those unable to attend.

Co-Diagnostics (NASDAQ:CODX) announced its participation at WHX Kuala Lumpur, Southeast Asia's leading healthcare exhibition, from July 16-18, 2025 at MITEC. The event, expecting over 10,000 visitors from 54 countries, will serve as a platform for CODX to showcase its PCR diagnostics portfolio.

The company will promote its Co-Primers® technology and introduce its upcoming Co-Dx™ PCR platform, including the Co-Dx PCR MTB test and 8-plex Co-Dx HPV test, both scheduled for clinical evaluations later this year. The company's participation is partially supported by a grant from World Trade Center Utah.

Co-Diagnostics (NASDAQ: CODX) announced its participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City. The conference aims to connect emerging growth companies with institutional investors. Company representatives will engage in one-on-one meetings to showcase their value proposition and introduce their upcoming Co-Dx PCR testing platform.

The company notes that their PCR platform, which includes the PCR Home™, PCR Pro™, mobile app, and associated tests, is currently pending regulatory review by the FDA and other bodies and is not yet commercially available.